Annual ROE
222.07%
+111.84%+101.46%
31 December 2023
Summary:
Halozyme Therapeutics annual return on equity is currently 222.07%, with the most recent change of +111.84% (+101.46%) on 31 December 2023. During the last 3 years, it has risen by +115.74% (+108.85%). HALO annual ROE is now -25.72% below its all-time high of 298.95%, reached on 31 December 2002.HALO ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly ROE
156.62%
-20.67%-11.66%
30 September 2024
Summary:
Halozyme Therapeutics quarterly return on equity is currently 156.62%, with the most recent change of -20.67% (-11.66%) on 30 September 2024. Over the past year, it has dropped by -16.61% (-9.59%). HALO quarterly ROE is now -97.57% below its all-time high of 6447.16%, reached on 31 December 2002.HALO Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HALO ROE Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +101.5% | -9.6% |
| 3 y3 years | +108.8% | -44.9% |
| 5 y5 years | +732.0% | +1082.6% |
HALO ROE High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -4.0% | +108.8% | -44.9% | +67.5% |
| 5 y | 5 years | -4.0% | +623.6% | -44.9% | +457.7% |
| alltime | all time | -25.7% | +111.3% | -97.6% | +100.2% |
Halozyme Therapeutics ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | 156.62%(-11.7%) |
| June 2024 | - | 177.29%(-19.1%) |
| Mar 2024 | - | 219.05%(+12.0%) |
| Dec 2023 | 222.07%(+101.5%) | 195.64%(+12.9%) |
| Sept 2023 | - | 173.23%(+15.2%) |
| June 2023 | - | 150.42%(+46.8%) |
| Mar 2023 | - | 102.50%(+3.2%) |
| Dec 2022 | 110.23%(-52.4%) | 99.36%(+6.2%) |
| Sept 2022 | - | 93.53%(-41.2%) |
| June 2022 | - | 158.95%(-32.3%) |
| Mar 2022 | - | 234.78%(-4.7%) |
| Dec 2021 | 231.44%(+117.7%) | 246.45%(-13.4%) |
| Sept 2021 | - | 284.47%(+35.1%) |
| June 2021 | - | 210.63%(+24.3%) |
| Mar 2021 | - | 169.44%(+32.7%) |
| Dec 2020 | 106.33%(-350.7%) | 127.70%(+611.8%) |
| Sept 2020 | - | 17.94%(-168.8%) |
| June 2020 | - | -26.09%(-40.4%) |
| Mar 2020 | - | -43.78%(+34.0%) |
| Dec 2019 | -42.41%(+20.7%) | -32.66%(+104.9%) |
| Sept 2019 | - | -15.94%(-5.9%) |
| June 2019 | - | -16.94%(-15.8%) |
| Mar 2019 | - | -20.13%(-39.0%) |
| Dec 2018 | -35.14%(-149.1%) | -33.00%(-250.3%) |
| Sept 2018 | - | 21.95%(-50.6%) |
| June 2018 | - | 44.40%(-29.2%) |
| Mar 2018 | - | 62.70%(-50.6%) |
| Dec 2017 | 71.60%(-103.7%) | 126.99%(-107.9%) |
| Sept 2017 | - | -1600.63%(-249.4%) |
| June 2017 | - | 1071.19%(+114.6%) |
| Mar 2017 | - | 499.09%(-136.7%) |
| Dec 2016 | -1958.98%(+2463.4%) | -1358.50%(+289.3%) |
| Sept 2016 | - | -348.93%(+71.7%) |
| June 2016 | - | -203.24%(+111.3%) |
| Mar 2016 | - | -96.17%(+21.7%) |
| Dec 2015 | -76.42%(-88.1%) | -79.03%(-24.1%) |
| Sept 2015 | - | -104.11%(+24.1%) |
| June 2015 | - | -83.89%(-29.0%) |
| Mar 2015 | - | -118.18%(-36.6%) |
| Dec 2014 | -640.16%(+10.7%) | -186.46%(-39.3%) |
| Sept 2014 | - | -307.15%(-19.9%) |
| June 2014 | - | -383.27%(-27.3%) |
| Mar 2014 | - | -526.96%(-13.9%) |
| Dec 2013 | -578.44% | -612.00%(+158.9%) |
| Sept 2013 | - | -236.39%(+50.5%) |
| June 2013 | - | -157.03%(+53.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2013 | - | -102.33%(-0.2%) |
| Dec 2012 | -179.24%(+41.7%) | -102.50%(-27.3%) |
| Sept 2012 | - | -141.08%(+38.7%) |
| June 2012 | - | -101.75%(+23.0%) |
| Mar 2012 | - | -82.75%(-23.1%) |
| Dec 2011 | -126.52%(-67.6%) | -107.59%(+36.8%) |
| Sept 2011 | - | -78.67%(-67.1%) |
| June 2011 | - | -239.44%(-51.7%) |
| Mar 2011 | - | -495.43%(-16.3%) |
| Dec 2010 | -390.69%(-25.4%) | -592.24%(-0.4%) |
| Sept 2010 | - | -594.84%(-23.2%) |
| June 2010 | - | -774.05%(+41.5%) |
| Mar 2010 | - | -546.89%(+29.8%) |
| Dec 2009 | -523.80%(+293.7%) | -421.42%(+25.7%) |
| Sept 2009 | - | -335.33%(+31.1%) |
| June 2009 | - | -255.78%(+33.2%) |
| Mar 2009 | - | -192.02%(+52.3%) |
| Dec 2008 | -133.03%(+125.1%) | -126.07%(+50.8%) |
| Sept 2008 | - | -83.58%(+28.6%) |
| June 2008 | - | -64.98%(+20.9%) |
| Mar 2008 | - | -53.76%(+15.8%) |
| Dec 2007 | -59.11%(-17.3%) | -46.41%(+1.9%) |
| Sept 2007 | - | -45.56%(-7.6%) |
| June 2007 | - | -49.29%(-26.0%) |
| Mar 2007 | - | -66.61%(-21.4%) |
| Dec 2006 | -71.46%(-11.1%) | -84.74%(-15.1%) |
| Sept 2006 | - | -99.87%(-8.7%) |
| June 2006 | - | -109.40%(-1.3%) |
| Mar 2006 | - | -110.83%(-0.2%) |
| Dec 2005 | -80.38%(-32.8%) | -111.04%(-21.3%) |
| Sept 2005 | - | -141.14%(+2.2%) |
| June 2005 | - | -138.08%(+1.5%) |
| Mar 2005 | - | -136.00%(-13.6%) |
| Dec 2004 | -119.64%(-78.9%) | -157.47%(-41.7%) |
| Sept 2004 | - | -269.89%(+39.3%) |
| June 2004 | - | -193.79%(-6.5%) |
| Mar 2004 | - | -207.24%(-95.9%) |
| Dec 2003 | -565.81%(-289.3%) | -5097.82%(-195.1%) |
| Sept 2003 | - | 5357.93%(-127.7%) |
| June 2003 | - | -19.34 K%(-80.6%) |
| Mar 2003 | - | -99.44 K%(-1642.4%) |
| Dec 2002 | 298.95%(-271.7%) | 6447.16%(<-9900.0%) |
| Sept 2002 | - | -18.73%(+147.4%) |
| June 2002 | - | -7.57%(-126.4%) |
| Mar 2002 | - | 28.66% |
| Dec 2001 | -174.12% | - |
FAQ
- What is Halozyme Therapeutics annual return on equity?
- What is the all time high annual ROE for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual ROE year-on-year change?
- What is Halozyme Therapeutics quarterly return on equity?
- What is the all time high quarterly ROE for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly ROE year-on-year change?
What is Halozyme Therapeutics annual return on equity?
The current annual ROE of HALO is 222.07%
What is the all time high annual ROE for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual return on equity is 298.95%
What is Halozyme Therapeutics annual ROE year-on-year change?
Over the past year, HALO annual return on equity has changed by +111.84% (+101.46%)
What is Halozyme Therapeutics quarterly return on equity?
The current quarterly ROE of HALO is 156.62%
What is the all time high quarterly ROE for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly return on equity is 6447.16%
What is Halozyme Therapeutics quarterly ROE year-on-year change?
Over the past year, HALO quarterly return on equity has changed by -16.61% (-9.59%)